sarecycline sarecycline sarecycline, sold under the brand name seysara , is a narrow-spectrum tetracycline-derived antibiotic medication. it is specifically designed for the treatment of acne, and was approved by the fda in october 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. two randomized and well-controlled clinical trials reported efficacy data on both facial and truncal acne (back and chest). efficacy was assessed in a total of 2002 subjects 9 years of age and older. unlike other tetracycline-class antibiotics, sarecycline has a long c7 moiety that extends into and directly interact with the bacterial messenger rna (mrna). the spectrum of activity is limited to clinically relevant gram-positive bacteria, mainly cutibacterium acnes, with little or no activity against gram-negative bacterial microflora commonly found in the human gastrointestinal tract. sarecyclineclinical datapronunciationsar"e sye' kleen trade namesseysaraother namesp-005672ahfs/drugs.commonographmedlineplusa618068license data us dailymed: sarecycline routes ofadministrationby mouthatc codej01aa14 (who) j01aa20 (who)legal statuslegal status us: ℞-only identifiers iupac name (4s,4as,5ar,12ar)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-7-methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide cas number1035654-66-0pubchem cid54681908as hcl: 71296095drugbankdb12035as hcl: dbsalt002125chemspider28540486unii94o110cx2ekeggd10666as hcl: d10667chemblchembl2364632pdb ligandv7a (pdbe, rcsb pdb)echa infocard100.241.852 chemical and physical dataformulac24h29n3o8molar mass487.509 g·mol−13d model (jsmol)interactive image smiles cn(c)12c3cc4=c(c=cc(=c4c(=c3c(=o)2(c(=c(c1=o)c(=o)n)o)o)o)o)cn(c)oc medical uses sarecycline, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.